PROJECT TEAM
Hengameh Chloe Lauridsen Ph.D. Researcher, Hvidovre Hospital FMT/FVT manufacture expert. Project manger
Morten Helms, Medical consultant Hvidovre Hospital rCDI patient and stool, donor responsible
Andreas Munk Petersen, Medical consultant Hvidovre Hospital, Advice regarding our clinical Trial and patient follow up
Frederic Cold MD. Ph.d. Hvidovre Hospital Clinical study responsible
THE NEED
There is currently no approved cure for rCDI, IBD, or IBS. These conditions severely impact patients' quality of life and place a growing financial burden on the healthcare system due to repeated hospitalizations and long-term treatment needs.
THE SOLUTION
The project offers the first fecal virus transplantation (FVT) capsule, using only the virus (bacteriophage) fraction from screened donor stool to safely and cost-effectively restore gut balance. This innovative treatment reduces the risk of pathogen transmission, improves outcomes, and lowers healthcare costs.
Fecal virus Transplantation capsule eradicate antibiotic resistance Cl. diff. - Hvidovre Hospital
Call 4 - 2023
500.000 DKK
Clinical Area
Gastro
Technology
Pills
PROJECT SUMMARY
This project develops the world’s first fecal virus transplantation (FVT) capsule—a safer, cheaper, and more scalable alternative to traditional fecal microbiota transplantation (FMT) for treating recurrent Clostridioides difficile infections (rCDI)
CLINICAL IMPACT
FVT-capsule improves patient quality of life by effective treatment without side effects, followed by significant reduced cost to healthcare. Fecal Microbiota Transplantation (FMT) is an effective therapy against rCDI, reducing hospitalization and medicine cost compared to the standard treatment.